CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Daré Bioscience, Inc. - DARE CFD

0.2861
9.52%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0056
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.3162
Open* 0.3182
1-Year Change* -64.14%
Day's Range* 0.2857 - 0.3184
52 wk Range 0.28-1.40
Average Volume (10 days) 356.84K
Average Volume (3 months) 5.16M
Market Cap 33.39M
P/E Ratio -100.00K
Shares Outstanding 98.56M
Revenue 1.00M
EPS -0.48
Dividend (Yield %) N/A
Beta 1.13
Next Earnings Date Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 7, 2023 0.3162 -0.0450 -12.46% 0.3612 0.3612 0.3068
Dec 6, 2023 0.3402 -0.0151 -4.25% 0.3553 0.3553 0.3382
Dec 5, 2023 0.3480 -0.0102 -2.85% 0.3582 0.3592 0.3447
Dec 4, 2023 0.3582 0.0040 1.13% 0.3542 0.3881 0.3482
Dec 1, 2023 0.3481 0.0025 0.72% 0.3456 0.3559 0.3387
Nov 30, 2023 0.3467 -0.0016 -0.46% 0.3483 0.3533 0.3412
Nov 29, 2023 0.3483 0.0063 1.84% 0.3420 0.3555 0.3332
Nov 28, 2023 0.3402 0.0020 0.59% 0.3382 0.3484 0.3328
Nov 27, 2023 0.3441 -0.0042 -1.21% 0.3483 0.3620 0.3312
Nov 24, 2023 0.3435 0.0203 6.28% 0.3232 0.3537 0.3232
Nov 22, 2023 0.3301 0.0018 0.55% 0.3283 0.3360 0.3277
Nov 21, 2023 0.3370 -0.0012 -0.35% 0.3382 0.3423 0.3232
Nov 20, 2023 0.3383 0.0071 2.14% 0.3312 0.3592 0.3312
Nov 17, 2023 0.3340 0.0008 0.24% 0.3332 0.3532 0.3150
Nov 16, 2023 0.3272 -0.0110 -3.25% 0.3382 0.3439 0.3232
Nov 15, 2023 0.3382 -0.0100 -2.87% 0.3482 0.3522 0.3337
Nov 14, 2023 0.3406 0.0097 2.93% 0.3309 0.3437 0.3249
Nov 13, 2023 0.3333 0.0251 8.14% 0.3082 0.3623 0.2992
Nov 10, 2023 0.3232 -0.0150 -4.44% 0.3382 0.3458 0.3232
Nov 9, 2023 0.3182 -0.0411 -11.44% 0.3593 0.3693 0.3182

Daré Bioscience, Inc. Events

Time (UTC) Country Event
Thursday, March 28, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Dare Bioscience Inc Earnings Release
Q4 2023 Dare Bioscience Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 10 0 0 0 0
Total Operating Expense 41.3855 38.6986 27.4023 14.3449 16.8823
Selling/General/Admin. Expenses, Total 11.3433 8.45095 6.63284 5.79877 5.28084
Research & Development 30.0422 30.6176 20.7694 8.54611 6.41396
Unusual Expense (Income) 0 -0.36989 0 5.18752
Operating Income -31.3855 -38.6986 -27.4023 -14.3449 -16.8823
Interest Income (Expense), Net Non-Operating
Net Income Before Taxes -30.9477 -38.6961 -27.4007 -14.2638 -16.7388
Net Income After Taxes -30.9477 -38.6961 -27.4007 -14.2638 -16.7388
Net Income Before Extra. Items -30.9477 -38.6961 -27.4007 -14.2638 -16.7388
Net Income -30.9477 -38.6961 -27.4007 -14.2638 -16.7388
Income Available to Common Excl. Extra. Items -30.9477 -38.6961 -27.4076 -15.0534 -16.7388
Income Available to Common Incl. Extra. Items -30.9477 -38.6961 -27.4076 -15.0534 -16.7388
Diluted Net Income -30.9477 -38.6961 -27.4076 -15.0534 -16.7388
Diluted Weighted Average Shares 84.5718 61.1542 30.0915 15.579 10.7324
Diluted EPS Excluding Extraordinary Items -0.36593 -0.63276 -0.91081 -0.96627 -1.55965
Diluted Normalized EPS -0.36593 -0.63881 -0.91081 -0.96627 -1.0763
Total Extraordinary Items
Other, Net 0.43775 0.00252 0.00151 0.08105 0.1435
Total Adjustments to Net Income 0 -0.00686 -0.78959
Revenue 10
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 10
Total Operating Expense 8.98936 8.38265 16.2306 7.13879 9.61568
Selling/General/Admin. Expenses, Total 2.94567 3.36243 3.25385 2.67654 2.81789
Research & Development 6.04368 5.02022 12.9767 4.46225 6.79778
Unusual Expense (Income) 0 0 0
Operating Income -8.98936 -8.38265 -16.2306 -7.13879 0.38432
Other, Net 0.22712 0.34015 0.28734 0.11895 0.02968
Net Income Before Taxes -8.76223 -8.0425 -15.9432 -7.01984 0.414
Net Income After Taxes -8.76223 -8.0425 -15.9432 -7.01984 0.414
Net Income Before Extra. Items -8.76223 -8.0425 -15.9432 -7.01984 0.414
Net Income -8.76223 -8.0425 -15.9432 -7.01984 0.414
Income Available to Common Excl. Extra. Items -8.76223 -8.0425 -15.9432 -7.01984 0.414
Income Available to Common Incl. Extra. Items -8.76223 -8.0425 -15.9432 -7.01984 0.414
Diluted Net Income -8.76223 -8.0425 -15.9432 -7.01984 0.414
Diluted Weighted Average Shares 86.4031 85.5175 81.6278 84.8225 85.3694
Diluted EPS Excluding Extraordinary Items -0.10141 -0.09405 -0.19532 -0.08276 0.00485
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.10141 -0.09405 -0.19532 -0.08276 0.00485
Total Adjustments to Net Income
Revenue 0 0 0 10
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 43.0387 55.296 6.98391 6.44393 7.24002
Cash and Short Term Investments 34.6696 51.6741 4.66947 4.78011 6.80589
Cash & Equivalents 34.6696 51.6741 4.66947 4.78011 6.80589
Total Assets 43.8264 55.8072 7.55071 7.44279 7.82739
Total Current Liabilities 31.6239 16.0529 7.6606 5.61241 1.09106
Payable/Accrued
Accrued Expenses 11.2924 3.40679 3.70743 2.50955 0.63135
Notes Payable/Short Term Debt 0 0 0.36729 0 0
Total Liabilities 32.7143 17.0529 8.70245 7.00196 1.10077
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.09035 1 1.04184 1.38956 0.00971
Total Equity 11.1121 38.7543 -1.15173 0.44083 6.72662
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.00848 0.00839 0.00416 0.00197 0.00114
Additional Paid-In Capital 152.53 149.028 70.3663 44.5647 35.792
Retained Earnings (Accumulated Deficit) -141.075 -110.127 -71.4308 -44.0232 -28.9698
Total Liabilities & Shareholders’ Equity 43.8264 55.8072 7.55071 7.44279 7.82739
Total Common Shares Outstanding 84.8255 83.9441 41.5962 19.6834 11.4222
Total Receivables, Net 1.70316 1.14532 0.46017 0.55521 0.03104
Prepaid Expenses 6.66599 2.47661 1.85428 1.10862 0.4031
Other Current Assets, Total 0
Goodwill, Net 0
Other Long Term Assets, Total 0.2648 0.26845 0.28932 0.44733 0.57797
Other Equity, Total -0.35131 -0.15497 -0.09139 -0.10263 -0.09673
Property/Plant/Equipment, Total - Net 0.52283 0.24271 0.27748 0.55153 0.0094
Accounts Payable 2.02795 2.10308 1.02133 1.08318 0.45971
Other Current Liabilities, Total 18.3036 10.543 2.56455 2.01967
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 22.4355 22.2433 29.5119 43.0387 49.5671
Cash and Short Term Investments 13.8944 13.3291 19.8294 34.6696 40.3895
Cash & Equivalents 13.8944 13.3291 19.8294 34.6696 40.3895
Total Receivables, Net 1.12976 0.57247 2.39871 1.70316 2.29204
Prepaid Expenses 6.57993 8.06962 7.08245 6.66599 6.8855
Total Assets 25.054 23.2099 30.3667 43.8264 50.3764
Property/Plant/Equipment, Total - Net 0.24062 0.32179 0.4234 0.52283 0.61883
Other Long Term Assets, Total 2.37791 0.64488 0.43133 0.2648 0.19051
Total Current Liabilities 26.3428 24.7008 24.3379 31.6239 22.8381
Accounts Payable 4.9874 6.54112 2.69561 2.02795 3.47719
Accrued Expenses 5.48783 4.46562 5.81597 11.2924 4.52447
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 15.8675 13.6941 15.8264 18.3036 14.8364
Total Liabilities 27.3428 25.9294 25.3951 32.7143 24.0327
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1 1.22853 1.05713 1.09035 1.19459
Total Equity -2.28874 -2.7194 4.9716 11.1121 26.3438
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.00983 0.00866 0.00862 0.00848 0.00848
Additional Paid-In Capital 164.299 155.556 154.453 152.53 151.997
Retained Earnings (Accumulated Deficit) -166.178 -157.879 -149.117 -141.075 -125.131
Other Equity, Total -0.4195 -0.40447 -0.37332 -0.35131 -0.53074
Total Liabilities & Shareholders’ Equity 25.054 23.2099 30.3667 43.8264 50.3764
Total Common Shares Outstanding 98.2923 86.6336 86.179 84.8255 84.8255
Accounts Receivable - Trade, Net
Other Current Assets, Total 0.83138 0.2721 0.20139
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -30.9477 -38.6961 -27.4007 -14.2638 -16.7388
Cash From Operating Activities -18.0884 -28.764 -25.2349 -13.3155 -10.2684
Non-Cash Items 2.13545 1.17796 0.57986 0.26014 5.83387
Cash Taxes Paid 0
Changes in Working Capital 10.6997 8.7277 1.54273 0.67707 0.63408
Cash From Investing Activities -0.06307 -0.01452 -0.01763 6.14389 -0.51884
Other Investing Cash Flow Items, Total 0 6.14389 -0.507
Cash From Financing Activities 1.34335 75.8468 25.1307 5.1517 10.1119
Issuance (Retirement) of Debt, Net 0 0.36729 0
Foreign Exchange Effects -0.19634 -0.06359 0.01124 -0.0059 -0.07865
Net Change in Cash -17.0045 47.0046 -0.11064 -2.02578 -0.75396
Cash Interest Paid 0
Cash From Operating Activities 0.0242 0.02641 0.04323 0.01114 0.00244
Capital Expenditures -0.06307 -0.01452 -0.01763 0 -0.01184
Issuance (Retirement) of Stock, Net 1.34335 75.8468 24.7634 5.1517 10.1119
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -8.0425 -30.9477 -15.0045 -7.98467 -8.39867
Cash From Operating Activities -16.1176 -18.0884 -12.1918 -20.792 -12.3435
Cash From Operating Activities 0.00951 0.0242 0.01358 0.01055 0.00523
Non-Cash Items 0.61872 2.13545 1.60922 1.07987 0.52265
Changes in Working Capital -8.70329 10.6997 1.18996 -13.8977 -4.47268
Cash From Financing Activities 1.29938 1.34335 1.34336 1.3389 0
Issuance (Retirement) of Stock, Net 1.29938 1.34335 1.34336 1.3389 0
Foreign Exchange Effects -0.02201 -0.19634 -0.37577 -0.14502 -0.00915
Net Change in Cash -14.8402 -17.0045 -11.2845 -19.6035 -12.3572
Cash From Investing Activities 0 -0.06307 -0.06037 -0.00537 -0.00455
Capital Expenditures 0 -0.06307 -0.06037 -0.00537 -0.00455
Issuance (Retirement) of Debt, Net
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.5045 3444675 -15545 2023-06-30 LOW
Johnson (Sabrina Martucci) Individual Investor 0.9788 962062 0 2023-04-07 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8315 817336 0 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.7313 718821 149762 2023-06-30 HIGH
Walters-Hoffert (Lisa) Individual Investor 0.4512 443512 0 2023-04-07 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.4054 398457 -210486 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.252 247710 0 2023-06-30 LOW
Steele Robin Joan Individual Investor 0.2504 246171 0 2023-04-07 LOW
Susquehanna International Group, LLP Investment Advisor 0.1669 164021 164021 2023-06-30 MED
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1641 161316 -352 2023-06-30 LOW
T. Rowe Price International Ltd Investment Advisor/Hedge Fund 0.1281 125900 0 2023-06-30 LOW
Founders Financial Securities, LLC Investment Advisor 0.1262 124000 10000 2023-09-30 MED
InterWest Partners Venture Capital 0.0631 62065 0 2023-09-30 LOW
Citadel Advisors LLC Hedge Fund 0.0508 49901 -194740 2023-06-30 LOW
Commonwealth Financial Network Investment Advisor 0.0502 49329 -250 2023-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.0311 30532 0 2023-06-30 LOW
BNY Mellon Asset Management Investment Advisor 0.0233 22947 0 2023-09-30 LOW
Raymond James Financial Services Advisors, Inc. Investment Advisor 0.0203 20000 -10 2023-09-30 LOW
Advisory Services Network, LLC Investment Advisor 0.0153 15000 0 2023-06-30 LOW
Lord, Abbett & Co. LLC Investment Advisor 0.0151 14808 0 2023-07-31 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Daré Bioscience, Inc. Company profile

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women''s health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company''s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.
Industry: Biotechnology & Medical Research (NEC)

3655 Nobel Dr Ste 260
SAN DIEGO
CALIFORNIA 92122-1050
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

BTC/USD

44,252.10 Price
+2.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.68 Price
+4.560% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading